Charles Schwab Investment Management Inc. reduced its position in PetMed Express, Inc. (NASDAQ:PETS - Free Report) by 46.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,186 shares of the company's stock after selling 96,449 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.53% of PetMed Express worth $526,000 as of its most recent SEC filing.
Separately, R Squared Ltd acquired a new stake in PetMed Express in the 4th quarter valued at $31,000. 73.33% of the stock is currently owned by institutional investors and hedge funds.
PetMed Express Trading Down 2.8 %
NASDAQ:PETS traded down $0.10 during trading hours on Friday, hitting $3.51. The stock had a trading volume of 246,814 shares, compared to its average volume of 306,623. The company has a market cap of $72.50 million, a PE ratio of 351.35 and a beta of 0.78. The business has a 50 day simple moving average of $4.36 and a two-hundred day simple moving average of $4.53. PetMed Express, Inc. has a 1-year low of $2.90 and a 1-year high of $6.85.
PetMed Express (NASDAQ:PETS - Get Free Report) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts' consensus estimates of ($0.01) by ($0.02). PetMed Express had a net margin of 0.14% and a return on equity of 0.37%. Research analysts expect that PetMed Express, Inc. will post 0.19 EPS for the current fiscal year.
Analysts Set New Price Targets
Separately, StockNews.com cut PetMed Express from a "buy" rating to a "hold" rating in a research note on Tuesday, February 11th.
Read Our Latest Analysis on PetMed Express
PetMed Express Profile
(
Free Report)
PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.
Recommended Stories

Before you consider PetMed Express, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PetMed Express wasn't on the list.
While PetMed Express currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.